iRhythm Q2 Earnings Call: Top 5 Analyst Questions
iRhythm reported second quarter results that beat analyst expectations, with revenue of $224.2 million versus estimates of $219.2 million, a 20.1% year-on-year increase, and adjusted EPS of $0.58 versus estimates of $0.04. The company also raised its full-year revenue guidance to $885 million at the midpoint from $880 million. During the earnings call, analysts focused on the VitalConnect acquisition, with CEO Quentin Blackford explaining that a multi-product approach is needed to cover the full spectrum of physician and patient preferences in the MCT market, and CFO Dan Wilson estimating share issuance would be less than 1.5% dilution. Other questions covered the sustainability of EBITDA margin gains, direct-to-patient marketing efforts, and potential cannibalization of iRhythm's own MCT development.
Yahoo Finance·11dRead more ▾
IRTC▼
iRhythm shares fall after Truist slashes price target to $18
Shares of iRhythm Technologies fell 2.8% in afternoon trading after Truist cut its price target on the stock to $18 from $160, overshadowing the company's strong second-quarter earnings report. Despite beating earnings estimates and raising full-year revenue guidance, investor focus turned to the drastic reduction, which likely signaled concern even though Truist maintained a Buy rating. The stock later pared losses to trade at $125.41, down 1.9% from the previous close. iRhythm is down 28.4% since the beginning of the year and trading 33.7% below its 52-week high of $189.25 from January 2026.
Yahoo Finance·14dRead more ▾
IRTC▲
iRhythm Holdings raises 2026 revenue guidance to $880–$890 million and proposes $45 million class action settlement
iRhythm Holdings reported second-quarter 2026 sales of $224.17 million and a narrowed net loss of $0.381 million, while raising its full-year 2026 revenue guidance to $880 million to $890 million and announcing a proposed $45.00 million securities class action settlement related to Zio AT device disclosures. The upgraded outlook and litigation progress come alongside the planned VitalConnect acquisition, giving investors a clearer view of both growth potential and legal overhang in the ambulatory cardiac monitoring business. The company’s narrative now projects $1.2 billion in revenue and $97.8 million in earnings by 2029, implying a fair value of $178.93 per share, a 40% upside to the current price.
Simply Wall St·19dRead more ▾
IRTC▼
Kuehn Law Investigates iRhythm Technologies Officers and Directors for Breach of Fiduciary Duties
Kuehn Law, PLLC is investigating whether certain officers and directors of iRhythm Technologies, Inc. breached their fiduciary duties to shareholders. The investigation stems from a federal securities lawsuit alleging that insiders caused the company to misrepresent or fail to disclose that the Zio AT monitor was a real-time monitor intended for high-risk patients, and that they touted its growth potential as an innovative product just beginning to penetrate the real-time monitoring market. These misrepresentations allegedly caused iRhythm common stock to trade at artificially inflated prices. Shareholders who currently own IRTC and purchased prior to November 5, 2021 are encouraged to contact the firm immediately, as there may be limited time to enforce their rights.
GlobeNewswire·29dRead more ▾
IRTC▲
StockStory highlights iRhythm as a healthcare stock to watch while flagging AdaptHealth and Collegium Pharmaceutical as sells
StockStory named iRhythm Technologies as a healthcare stock to watch, citing its 23.9% annual revenue growth over two years and a move to positive free cash flow, while recommending investors avoid AdaptHealth and Collegium Pharmaceutical. AdaptHealth saw flat sales and a 12.4% annual decline in earnings per share over five years, with a 0.3% return on capital. Collegium Pharmaceutical's adjusted operating margin fell 6.4 percentage points as costs outpaced revenue, and its returns on capital stagnated. iRhythm trades at 351.1 times forward earnings, AdaptHealth at 11 times, and Collegium at 4.5 times.
StockStory·41dRead more ▾
IRTC▲
StockStory flags Lucid and 10x Genomics as sells, iRhythm as a watchlist pick
StockStory highlights one unprofitable stock to watch and two to avoid. Lucid Group, with a trailing 12-month GAAP operating margin of negative 271%, is flagged for its negative 136% gross margin and cash-burning history that raises dilution risk. 10x Genomics, at a negative 6.1% operating margin, is cited for sluggish 1.1% annual revenue growth and negative returns on capital. iRhythm Technologies, with a negative 5.2% operating margin, earns a watchlist spot due to 23.9% annual revenue growth and a positive free cash flow profile.
StockStory·51dRead more ▾
IRTC▲
Patient monitoring stocks beat Q1 revenue estimates by 2.3% but guidance disappoints
The four patient monitoring stocks tracked by this review reported a strong first quarter, with aggregate revenues beating analysts' consensus estimates by 2.3%, though next quarter's revenue guidance came in 0.8% below expectations. Insulet led the group with revenues of $761.7 million, up 33.9% year on year and exceeding estimates by 4.2%, while also posting the fastest revenue growth and biggest analyst estimate beat. iRhythm Technologies reported revenues of $199.4 million, up 25.7% year on year and beating estimates by 2.8%, and delivered the highest full-year guidance raise among its peers. ResMed posted revenues of $1.43 billion, up 10.8% year on year and exceeding estimates by 0.8%, but recorded the weakest performance against analyst estimates and slowest revenue growth in the group. DexCom reported revenues of $1.19 billion, up 15% year on year and topping estimates by 1.4%, though it had the weakest full-year guidance update among its peers.
Yahoo Finance·57dRead more ▾
IRTC▼
iRhythm Holdings Dropped Despite Beat-And-Raise Results, Says Carillon Eagle Fund
iRhythm Holdings shares fell even after the company posted beat-and-raise results, according to the Carillon Eagle Small Cap Growth Fund's first-quarter 2026 investor letter. The fund cited broader weakness in the healthcare equipment and supplies industry as investors rotated into cyclical and technology stocks. Additional pressure came from a US Department of Justice Civil Investigative Demand received in December related to mobile cardiac telemetry services rendered in 2023 via iRhythm's Zio AT device, though the inquiry is limited in scope and accounts for only a small portion of total sales. The fund noted the risk has already been priced in and did not read much into the company's recent change of auditors. iRhythm Holdings closed at $112.47 per share on June 24, 2026, with a one-month return of negative 2.72% and a 52-week loss of 26.34%.
Insider Monkey·62dRead more ▾
IRTC▲
StockStory Highlights iRhythm as Cash-Producing Stock to Watch, Flags Lennar and Verisk as Underwhelming
StockStory identifies iRhythm Technologies as a cash-producing stock to target this week while recommending investors avoid Lennar and Verisk. iRhythm, which provides wearable cardiac monitoring devices, posted 23.9% annual revenue growth over the past two years and saw free cash flow turn positive over five years, with earnings per share growing 27.5% annually. Lennar, one of America's largest homebuilders, is flagged for a 9.2% average backlog decline over two years and an 8.9% annual drop in earnings per share despite revenue growth. Verisk Analytics, a data and analytics provider for insurers, is criticized for 1.9% annual revenue growth over five years and earnings per share growth of just 9.3% annually over the past two years.
StockStory·68dRead more ▾